Navigation Links
Myeloma in Medical News

Multiple Myeloma Genome Unlocked

Discovery paves way for better therapies for some blood cancer patients, experts say WEDNESDAY, July 29 (HealthDay News) -- The sequencing of the first three multiple myeloma whole genomes has been completed by U.S. scientists, who said this success will lead to a better understanding ...

CancerCare Launches New Program to Help Multiple Myeloma Patients Cover Transportation Costs

NEW YORK, July 20 /PRNewswire/ -- Cancer Care announced today the launch of the "Door to Door" program for patients with multiple myeloma. Cancer Care 's program will provide individual grants of up to $600 annually to multiple myeloma patients for covering transportation cost...

New Report Just Published: World Multiple Myeloma Therapeutics Market Report

NEW YORK, July 7 /PRNewswire/ -- Reportlinker.com just added a new market research report to its catalogue. World Multiple Myeloma Therapeutics Market http://www.reportlinker.com/p0119496/World-Multiple-Myeloma-Therapeutics-Market.html?utm_source=PRNWire&utm_medium=PR&utm...

MMRF and the Broad Institute to perform whole genome sequencing of multiple myeloma samples

The Multiple Myeloma Research Foundation (MMRF) announced today a collaboration with the Broad Institute of MIT and Harvard to systematically uncover the molecular changes underlying multiple myeloma by whole genome sequencing of individual patient tumors. The MMRF will provide both patient sample...

Data on VELCADE(R) (Bortezomib) for Injection Based Therapies to be Presented at the International Myeloma Workshop

CAMBRIDGE, Mass., Feb. 23 /PRNewswire/ -- Millennium: The Takeda Oncology Company today announced that 100 data presentations on VELCADE research will be featured at the Fifth International Myeloma Workshop (IMW) in Washington, D.C., February 26 - March 1, 2009. The 13 oral and 87 poster presenta...

International Panel of Experts Gather for Roundtable Consensus Regarding Multiple Myeloma Related Disease

LOS ANGELES, Feb. 23 /PRNewswire-USNewswire/ -- On Wednesday, February 25, 2009, the Institute for Myeloma and Bone Cancer Research (IMBCR) will host a roundtable discussion bringing leading scientists in the field of cancer research together to discuss monoclonal gammopathy of undetermined signif...

Managing Myeloma (www.managingmyeloma.com) Launches - A Comprehensive Information and Educational Site for Physicians, Nurse Practitioners, Physician Assistants, and Pharmacists

MORRISVILLE, Pa., Feb. 12 /PRNewswire/ -- MediCom Worldwide, Inc., an accredited provider of continuing medical education for physicians, pharmacists, and nurses, announces the launch of an online repository of resources and education on the treatment of multiple myeloma by a multidisciplinary net...

Institute of Myeloma and Bone Cancer Research in Los Angeles Proudly Announces That Ethan Horwitz, Esq of King & Spalding Law Firm has Joined its Board of Directors

LOS ANGELES, Feb. 6 /PRNewswire-USNewswire/ -- Established in 2004, the Institute for Myeloma and Bone Cancer Research (IMBCR) is the only non-profit, independent cancer research institute focused on creating novel therapies and ultimately a cure for multiple myeloma and metastatic bone disease. ...

Senesco Announces Results of Pre-Clinical Efficacy, Toxicology and Dose Ranging Studies for Multiple Myeloma Therapeutic Candidate

NEW BRUNSWICK, N.J., Feb. 3 /PRNewswire-FirstCall/ -- Senesco Technologies, Inc. ("Senesco" or the "Company") (NYSE Alternext US : SNT) today announced results of efficacy, toxicological and dose-finding studies in mice for its potential multiple myeloma drug candidate, SNS-01. SNS-01 is a n...

1.2 Million Dollars Recently Awarded to Institute for Myeloma and Bone Cancer Research

FJC, a foundation of philanthropic donor-advised funds and the Myeloma Research Foundation are the latest major donors to the "Cure Myeloma Project", an ongoing research initiative at the Institute for Myeloma and Bone Cancer Research, (IMBCR), in Los Angeles, CA LOS ANGELES, Jan. 26 /PRNewsw...

Combo Therapy Helps Multiple Myeloma Patients

Three-quarters of those who had relapsed saw disease stabilize or improve, study shows FRIDAY, Dec. 12 (HealthDay News) -- A new combination of medicines designed to boost immune function can help some multiple myeloma patients, according to interim results from an ongoing Mayo Clinic ...

Drug combination improves or stabilizes disease for relapsed multiple myeloma patients

ROCHESTER, Minn. -- Mayo Clinic researchers have found that a new combination of medications designed to maximize immune functions improved or stabilized multiple myeloma for 76 percent of patients who had relapsed after previous treatment. Interim results of an ongoing clinical trial evaluati...

Treatment with anti-anemia drugs may not be safe for multiple myeloma patients

Thessaloniki, Greece - August 4, 2008 - A recent study published in American Journal of Hematology demonstrated that Erythropoiesis-stimulating agents (ESAs), a widely used drug to treat anemia, may have a negative impact on the survival of myeloma patients. In the study, 323 multiple myeloma pa...

How molecules out of balance lead to human multiple myeloma and other cancers

An international team of scientists has identified processes that are heavily implicated in human multiple myeloma and other B cell cancers, moving us closer to developing quick tests and readouts that could help in the tailored treatment of patients. B cells, the white blood cells that produce...

Senesco Expands on Preclinical Multiple Myeloma Findings

NEW BRUNSWICK, N.J., June 5 /PRNewswire-FirstCall/ -- Senesco Technologies, Inc. ("Senesco" or the "Company") (Amex: SNT ) announced today further details of its continuing preclinical multiple myeloma research. In February 2008, the Company announced results of preclinical animal studies in ...

McCarty Cancer Foundation Awards $50,000 Grant for Myeloma Research Program at Karmanos Cancer Institute

DETROIT, April 11 /PRNewswire-USNewswire/ -- The McCarty Cancer Foundation has awarded Jeffrey Zonder, M.D., Assistant Professor of Medicine and Oncology, Barbara Ann Karmanos Cancer Institute and Wayne State University School of Medicine, a $50,000 grant for the multi-center Multiple Myeloma ...

Publication of Clinical Results Underscores VELCADE(R) (Bortezomib) For Injection Based Therapy As a Standard of Care In Newly Diagnosed Multiple Myeloma Patients

-- Trial results of combination therapy VELCADE, melphalan and prednisone reported a 32 percent complete remission rate with 85 percent of patients alive at three years -- CAMBRIDGE, Mass., March 13 /PRNewswire-FirstCall/ -- Millennium Pharmaceuticals, Inc. (Nasdaq: MLN...

VELCADE(R) (Bortezomib) for Injection Based Therapy Produced Significant Complete Remission Rates Pre- and Post-Transplantation in IFM Phase III Front-Line Multiple Myeloma Trial

ATLANTA, Dec. 10 /PRNewswire-FirstCall/ -- Millennium Pharmaceuticals, Inc. (Nasdaq: MLNM ) today reported the presentation of results from a 482 patient, multi-center, randomized Phase III clinical trial, comparing VELCADE and dexamethasone (VcD) to vincristine, adriamycin and dexamethasone ...

New therapeutic options for newly diagnosed multiple myeloma patients

ATLANTA -- Mayo Clinic researchers today presented results of a phase II trial of myeloma induction therapy -- a first step therapy designed to reduce cancer cells numbers -- with cyclophosphamide, bortezomib, and dexamethasone (Cybor-D) showing an improved response over the traditional lenalidomi...

Thalidomide Added to Standard Therapy Prolongs Overall Survival in Newly Diagnosed Multiple Myeloma Patients Over Age 75

- Data Demonstrate 17.6 Month Overall Survival Advantage in Elderly Myeloma Patients when Thalidomide Is Added to Standard Therapy - Data Presented at the 49th American Society of Hematology Meeting ATLANTA, Dec. 9 /PRNewswire-FirstCall/ -- Pharmion Corporation (Nasdaq: PHRM) today anno...

Highest Reported Complete Remission Rate of 35 Percent Achieved in a Phase III Front-Line Multiple Myeloma Trial With Velcade(R) (Bortezomib) for Injection Based Therapy

- VELCADE based therapy achieved highly significant improvement across all efficacy endpoints including overall survival - ATLANTA, Dec. 9 /PRNewswire-FirstCall/ -- Millennium Pharmaceuticals, Inc. (Nasdaq: MLNM ) today announced the presentation of results from the 682 patient, ran...

Drug Combo Boosts Multiple Myeloma Survival

A thalidomide derivative plus dexamethasone improved outcomes, studies found WEDNESDAY, Nov. 21 (HealthDay News) -- A combination drug regimen that includes a derivative of thalidomide extended survival, as well as the time it took for the disease to reappear, in patients with multiple...

Studies attribute recent increase in multiple myeloma survival to novel therapies

(WASHINGTON, November 1, 2007) Multiple myeloma is one of the most common and devastating bone marrow cancers in the U.S., but survival rates have risen dramatically over the past decade. Recent analyses suggest that this trend may be attributed to new types of drugs and aggressive therapeutic in...

Thalidomide Improves Outcomes for Older Myeloma Patients

Adding the drug to standard chemo boosted survival, study found FRIDAY, Oct. 5 (HealthDay News) -- Elderly patients with multiple myeloma live longer when thalidomide is added to standard combination chemotherapy treatment, a new study finds. The finding could be the first real treatment adv...

Gene Test Could Boost Myeloma Treatment

Certain DNA influences who'll respond best to therapy, scientists say THURSDAY, Sept. 20 (HealthDay News) -- Analyzing the activity of a small subset of genes may help identify patients with the worst cases of multiple myeloma, U.S. researchers say. It may also help guide their treatment, not...

Gene profiling can single out the worst cases of multiple myeloma and guide therapy

ATLANTA Multiple myeloma patients vary widely in how they respond to treatment, but now researchers at the Myeloma Institute for Research and Therapy at the University of Arkansas for Medical Sciences have identified a small subset of genes whose activity could predict high-risk cases and potenti...

Human C-reactive protein regulates myeloma tumor cell growth and survival

Scientists report that a protein best known as a common marker of inflammation plays a key role in the progression of human cancer. The research, published by Cell Press in the September issue of the journal Cancer Cell, implicates C-reactive protein (CRP) as a potential target for cancer treatmen...

Keryx Biopharmaceuticals Announces Agreement with FDA on a Special Protocol Assessment for Phase 3 Trial of KRX-0401 (Perifosine) in the Treatment of Multiple Myeloma

NEW YORK, Aug. 3 /PRNewswire-FirstCall/ -- Keryx Biopharmaceuticals, Inc. (Nasdaq: KERX ) announced today that it has reached agreement with the U.S. Food and Drug Administration (FDA) regarding a Special Protocol Assessment (SPA) on the design of a Phase 3 trial for its PI3K/Akt pathw...

Combination Therapy Helps to Combat Myeloma

Adding Velcade to standard drug therapy prolonged survival, study finds WEDNESDAY, Aug. 27 (HealthDay News) -- Patients with multiple myeloma who could not tolerate high dose chemotherapy lived longer and better by adding the drug Velcade to standard treatment, a new study found. Th...

Thalidomide Continues to Show Benefits Against Myeloma

The once-notorious drug aiding certain patients with the blood cancer WEDNESDAY, July 9 (HealthDay News) -- Researchers exploring the benefits of the once-banned drug thalidomide for patients with myeloma have learned a lesson that's as true to life as it is to science: Don't judge res...

One Gene May Be Key to Myeloma

The discovery holds promise as a treatment target for this diverse disease, experts say MONDAY, June 23 (HealthDay News) -- Cancerous myeloma cells are so "addicted" to a gene known as IRF4, they simply can't live without it, new research has revealed. Reducing the activity of the g...

FDA Approves VELCADE(R) (Bortezomib) for Injection for Patients with Previously Untreated Multiple Myeloma

- New indication offers earlier treatment options for patients - CAMBRIDGE, Mass. and OSAKA, Japan, June 20 /PRNewswire/ -- Millennium Pharmaceuticals, The Takeda Oncology Company, and Takeda Pharmaceutical Company Limited ("Takeda", TSE: 4502) today announced that the U.S. Food and Drug A...

Kosan Opens TIME-1 Pivotal Phase 3 Trial in Multiple Myeloma

Kosan Leads Industry with Most Advanced Hsp90 Inhibitor in Clinical Development New Supportive Trial in Less Refractory Patients to Replace Current TIME-2 Trial Conference Call and Webcast Today HAYWARD, Calif., ...

Millennium Submits sNDA for VELCADE(R) (Bortezomib) for Injection for the Treatment of Front-Line Multiple Myeloma

CAMBRIDGE, Mass., Dec. 21 /PRNewswire-FirstCall/ -- Millennium Pharmaceuticals, Inc. (Nasdaq: MLNM ) today announced the submission of a supplemental new drug application (sNDA) with the U.S. Food and Drug Administration (FDA) for VELCADE in the treatment of patients with previously untreated...

3-drug combination 'extremely promising' as first-line therapy for multiple myeloma

ATLANTAA new combination of bortezomib (Velcade) and two other drugs is showing a very high response rate in patients newly diagnosed with multiple myeloma, a team headed by Dana-Farber Cancer Institute investigators reported at the annual meeting of the American Society of Hematology. The thre...

Phase III Trial of VELCADE(R) (Bortezomib) for Injection Showed Dramatic Fourfold Increase in Complete Remission Rates When Combined With the Most Commonly Used U.S. Regimen in Front-Line Multiple Myeloma

- VELCADE, thalidomide and dexamethasone improved pre - and post-stem cell transplantation results compared to thalidomide and dexamethasone - ATLANTA, Dec. 9 /PRNewswire-FirstCall/ -- Millennium Pharmaceuticals, Inc. (Nasdaq: MLNM ) reported the presenta...

Penn's Abramson Cancer Center part of major phase III study for myeloma

PHILADELPHIA Researchers from the Abramson Cancer Center of the University of Pennsylvania announced today that findings from two large, international clinical trials show unprecedented survival for patients with multiple myeloma, a cancer that occurs in the blood-making cells of bone marrow. The...

FDA Expands VELCADE(R) (Bortezomib) for Injection Label for Patients with Multiple Myeloma

- Underscores Benefit for Patients with Kidney Impairments - - Highlights Leading Role of VELCADE in Broad Range of Patients - CAMBRIDGE, Mass., Oct. 15 /PRNewswire-FirstCall/ -- Millennium Pharmaceuticals, Inc. (Nasdaq: MLNM ) today announced that the U.S. Food and Drug Administratio...

The Leukemia & Lymphoma Society Provides Patients with the Latest Information on Myeloma

Free, Interactive Telephone Education Program Features Myeloma Experts, Melissa Alsina, M.D. and Kathy A. Daily, R.N. WHITE PLAINS, N.Y., Oct. 4 /PRNewswire/ -- Myeloma patients can learn about managing side effects during a free telephone education workshop sponsored by The Leukem...

Emory researchers identify signaling protein for multiple myeloma

Researchers at Emory Universitys Winship Cancer Institute are the first to discover a mechanism that plays a critical role in the multiple myeloma cell cycle and survival. Their research may result in identification of a new therapeutic target for treating multiple myeloma. The results of the ...
Other Tags
(Date:7/31/2014)... Bureau, Latinos are the largest minority group in the ... one-third of Latinos are obese and are 1.2 times ... , NYU College of Nursing student researcher Lauren ... the factors that contribute to this problem by compiling ... food patterns in Latina women recently published in ...
(Date:7/31/2014)... (HPV-023; NCT00518336) shows the sustained efficacy, immunogenicity ... (HPV) vaccine Cervarix. Women vaccinated with the ... than nine years, and vaccine efficacy (VE) ... the longest follow-up report for a licensed ... the full paper. , HPV and ...
(Date:7/31/2014)... An international team of scientists from Spain, France, ... rove beetle that is the oldest definitive member ... found in amber. The discovery and description were ... phase-contrast X-ray synchrotron imaging technique, which allows the ... amber. The new species is described in the ...
Breaking Biology News(10 mins):NYU research looks to combat US Latina immigrant obesity 2Sustained efficacy, immunogenicity, and safety for GlaxoSmithKline's HPV vaccine 2Sustained efficacy, immunogenicity, and safety for GlaxoSmithKline's HPV vaccine 3
(Date:8/1/2014)... at the University of California, San Diego School of ... in chili peppers produces chronic activation of a ... a reaction that ultimately reduces the risk of colorectal ... 1, 2014 issue of The Journal of Clinical ... TRPV1, was originally discovered in sensory neurons, where it ...
(Date:8/1/2014)... brain plays a central role in regulating appetite and ... in the brain,s control of food intake and body ... process has been unclear. A new study ... that PPARγ activity in a type of neuron known ... response to high-fat diet. Sabrina Diano and colleagues ...
(Date:8/1/2014)... HealthDay Reporter FRIDAY, Aug. 1, 2014 (HealthDay News) ... have significantly less endurance than those who weigh less, a new ... were obese, half were of normal weight -- people who were ... Obesity also was associated with less strength, increased discomfort and ... to 65 years of age -- neither improved nor reduced a ...
(Date:8/1/2014)... -- The U.S. Food and Drug Administration announced on ... help fight type 2 diabetes. Jardiance (empagliflozin) ... regimens to control blood sugar levels in the overall ... Office of Drug Evaluation II in the FDA,s Center ... statement. The FDA also recommended that Jardiance be ...
(Date:8/1/2014)... study, researchers at University Hospitals Rainbow Babies & Children,s ... at greater risk for death on a commercial airline ... worldwide between January 2010 and June 2013 and found ... age of 2. , The study was conducted ... of an in-flight pediatric fatality onboard commercial airline flights ...
Breaking Medicine News(10 mins):Health News:Pepper and halt: Spicy chemical may inhibit gut tumors 2Health News:Obesity Might Slow You Down at Work 2Health News:Obesity Might Slow You Down at Work 3Health News:FDA Approves New Type 2 Diabetes Drug 2Health News:New research characterizes in-flight pediatric deaths 2
Other Contents